...
首页> 外文期刊>Italian Journal of Public Health >Allocating the Sample Size in Phase II and III Trials to Optimize Success Probability
【24h】

Allocating the Sample Size in Phase II and III Trials to Optimize Success Probability

机译:在第二阶段和第三阶段试验中分配样本量以优化成功概率

获取原文

摘要

{f Background} Clinical trials of phase II and III often fail due to poor experimental planning. Here, the problem of allocating available resources, in terms of sample size, to phase II and phase III is studied with the aim of increasing success rate. The overall success probability (OSP) is accounted for. {f Methods} Focus is placed on the amount of resources that should be provided to phase II and III trials to attain a good level of OSP, and on how many of these resources should be allocated to phase II to optimize OSP. It is assumed that phase II data are not considered for confirmatory purposes and that are used for planning phase III through sample size estimation. Being $r$ the rate of resources allocated to phase II, $OSP(r)$ is a concave function and there exists an optimal allocation $r_{opt}$ giving $max{OSP}$. If $M_I$ is the sample size giving the desired power to phase III, and $kM_I$ is the whole sample size that can be allocated to the two phases, it is indicated how large $k$ and $r$ should be in order to achieve levels of OSP of practical interest. {f Results} For example, when 5 doses are evaluated in phase II and 2 parallel phase III confirmatory trials (one-tail type I error $=2.5%$, power $=90%$) are considered with 2 groups each, $k=24$ is needed to obtain $OSPsimeq 75%$, with $r_{opt}simeq 50%$. The choice of $k$ depends mainly on how many phase II treatment groups are considered, not on the effect size of the selected dose. When $k$ is large enough, $r_{opt}$ is close to $50%$. An $rsimeq25%$, although not best, might give a good OSP and an invitingly small total sample size, provided that $k$ is large enough. {f Conclusions} To improve the success rate of phase II and phase III trials, the drug development could be looked at in its entirety. Resources larger than those usually employed should be allocated to phase II to increase OSP. Phase II allocation rate may be increased to, at least, 25%, provided that a sufficient global amount of resources is available.
机译:{ bf背景} II和III期临床试验通常由于不良的实验计划而失败。这里,为了提高成功率,研究了在样本量方面将可用资源分配给第二阶段和第三阶段的问题。考虑了总体成功概率(OSP)。 { bf方法}重点放在为达到良好的OSP水平而应向II和III期试验提供的资源量上,以及应将这些资源中的多少分配给II期以优化OSP。假设不考虑将第二阶段的数据用于确认目的,而是通过样本量估计来计划第三阶段的数据。作为$ r $分配给第二阶段的资源比率,$ OSP(r)$是一个凹函数,并且存在给出$ max {OSP } $的最优分配$ r_ {opt} $。如果$ M_I $是为第三阶段提供所需功效的样本量,而$ kM_I $是可以分配给两个阶段的整个样本量,则表明$ k $和$ r $应该有多大达到具有实际意义的OSP水平。 { bf结果}例如,当在II期评估5剂剂量和2项平行III期验证性试验(单尾I型误差$ = 2.5 %$,功效$ = 90 %$)评估为2组时每个都需要$ k = 24 $来获得$ OSP simeq 75 %$,以及$ r_ {opt} simeq 50 %$。 $ k $的选择主要取决于要考虑的II期治疗组数,而不取决于所选剂量的作用大小。当$ k $足够大时,$ r_ {opt} $接近$ 50 %$。 $ r simeq25 %$虽然不是最好的,但只要$ k $足够大,它可能会提供良好的OSP和较小的总样本量。 { bf结论}为了提高II期和III期试验的成功率,可以从整体上看待药物开发。应将比通常使用的资源大的资源分配给第二阶段,以增加OSP。如果有足够的全局资源可用,第二阶段的分配率可以提高到至少25%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号